Moreover, some researchers found that the frequency of PD1+ CD8+ T cells in the tumor microenvironment, which negatively impacts effector and immunosuppressive functions, can predict the clinical efficacy of PD1 inhibitors better than PD1 or PD‐L1 expression or TMB.30 The gene discussed is CD274; the disease is neoplasm.